Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities (2023 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Total Non-Current Liabilities of $1.3 million for Q4 2025, up 95.82% year-over-year from $668235.5 in Q4 2024, and up 99.47% quarter-over-quarter from $656000.0 in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Total Non-Current Liabilities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 95.82% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (up 95.82% YoY), while the FY2025 annual figure was $1.3 million, up 101.82% from the prior year.
- Total Non-Current Liabilities climbed to $1.3 million in Q4 2025 per ZYBT's latest filing, from $656000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $1.4 million in Q4 2023 and bottomed at $656000.0 in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $1.0 million across 3 years, with a median of $988393.9 in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 53.66% — and 2025, when it surged 95.82%.
- Zhengye Biotechnology Holding's Total Non-Current Liabilities stood at $1.4 million in 2023, then plunged by 53.66% to $668235.5 in 2024, then soared by 95.82% to $1.3 million in 2025.
- Business Quant data shows ZYBT's Total Non-Current Liabilities at $1.3 million in Q4 2025, $656000.0 in Q2 2025, and $668235.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Zhengye Biotechnology Holding | 86.79 Mn | 79.48 Mn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Mn |
| Jun 30, 2025 | 656,000.00 |
| Dec 31, 2024 | 668,235.45 |
| Dec 31, 2023 | 1.44 Mn |